Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Cytarabine/dasatinib/methotrexate

Lack of efficacy: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Dragoescu M, et al. Inotuzumab Ozogamicin in the Treatment of Relapsed/Refractory (R/R) Ph-Positive Acute Lymphoid Leukemia (ALL) With Extramedullary Disease: Our Experience. Clinical Lymphoma, Myeloma & Leukemia 23 (Suppl. 1): S248, Sep 2023. Available from: URL: http://doi.org/10.1016/S2152-2650%2823%2900952-7 [abstract] Dragoescu M, et al. Inotuzumab Ozogamicin in the Treatment of Relapsed/Refractory (R/R) Ph-Positive Acute Lymphoid Leukemia (ALL) With Extramedullary Disease: Our Experience. Clinical Lymphoma, Myeloma & Leukemia 23 (Suppl. 1): S248, Sep 2023. Available from: URL: http://​doi.​org/​10.​1016/​S2152-2650%2823%2900952-7 [abstract]
Metadaten
Titel
Cytarabine/dasatinib/methotrexate
Lack of efficacy: 2 case reports
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-48726-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs